Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

People who commonly experience everyday discrimination are more likely to have higher levels of "exhausted" white blood cells, suggesting that the chronic stress of discrimination may hamper the ...

The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...

Allergic diseases represent a major global health burden, placing significant strain on health care systems worldwide. Severe ...